The White House is planning to officially launch its direct-to-consumer, lower-cost drug platform TrumpRx​.com on Thursday evening, unveiling the results of President Donald Trump’s “Most Favored Nation” (MFN) drug pricing policy.

In a new statement, Cato health policy expert, Dr. Jeffrey Singer says: “President Donald Trump is right that direct-to-consumer drug sales can lower prices by restoring cost consciousness to patients. When third parties pay most of the bill, consumers are insulated from prices and providers face less pressure to compete on cost. But a government-run platform isn’t necessary to achieve that goal. Private firms are already expanding direct-to-consumer options, and federal involvement risks crowding out competition and introducing political favoritism into a market that might finally be becoming more consumer-driven.”

Singer will be available to speak on this matter, please feel free to reach out to Emily at esalamon@​cato.​org